ReviewCurrent pathobiology reports2018
Life History Trade-Offs in Tumors.
Review in Current pathobiology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Eco-Evolutionary Dynamics of Proliferation Heterogeneity: A Phenotype-Structured Model for Tumor Growth and Treatment Response.Bulletin of mathematical biology · 2026Article
- Fibroblast activation protein (FAP)-mediated promotion of metastasis via the FN1-TGFβ axis and immune suppression in aggressive thyroid cancer.Journal of translational medicine · 2025Article
- Life history dynamics of evolving tumors: insights into task specialization, trade-offs, and tumor heterogeneity.Cancer cell international · 2024Review
- A war on many fronts: cross disciplinary approaches for novel cancer treatment strategies.Frontiers in genetics · 2024Review
- Modeling cell populations metabolism and competition under maximum power constraints.PLoS computational biology · 2023Article
- Toward a theory of evolution as multilevel learning.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- The Cellular Prion Protein and the Hallmarks of Cancer.Cancers · 2021Review
- Review
- Variation in the life history strategy underlies functional diversity of tumors.National science review · 2021Article
- Searching for Goldilocks: How Evolution and Ecology Can Help Uncover More Effective Patient-Specific Chemotherapies.Cancer research · 2020Review
- Eco-oncology: Applying ecological principles to understand and manage cancer.Ecology and evolution · 2020Review
- Cancer cell lines show high heritability for motility but not generation time.Royal Society open science · 2020Article
- Molecular Biology and Evolution of Cancer: From Discovery to Action.Molecular biology and evolution · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposeIn this paper, we provide an overview of a life history theory and how it applies to cancer evolution. RECENT
findingsWe review the literature on trade-offs in tumors, focusing on the trade-offs among cellular proliferation, survival, and motility. Trade-offs are critical natural constraints for almost all evolutionary processes. Many ecological studies show that trade-offs among these cellular functions maintain a genetic diversity. In addition, these trade-offs are not fixed, but rather can shift depending on the ecological circumstances in the microenvironment. This can lead to selection for the cellular capacity to respond to these differing microenvironments in ways that promote the fitness of the cancer cell. We relate these life history trade-offs to the recently developed Evo-Eco indexes and discuss how life history theory can help refine our measures of tumor evolution and ecology. SUMMARY: Life history theory provides a framework for understanding how the spatial and temporal variability in the tumor microenvironment-in particular resources and threats-affect trade-offs among cell survival, cell proliferation, and cell migration. We discuss how these trade-offs can potentially be leveraged in cancer therapy to increase the effectiveness of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.